Tetraspanins CD81 and CD82 Facilitate α4β1-Mediated Adhesion of Human Erythroblasts to Vascular Cell Adhesion Molecule-1

Frances A. Spring1, Rebecca E. Griffiths1, Tosti J. Mankelow1, Christopher Agnew2, Stephen F. Parsons1, Joel A. Chasis3, David J. Anstee1

1 Bristol Institute for Transfusion Sciences, Bristol, United Kingdom, 2 Department of Biochemistry, University of Bristol, Bristol, United Kingdom, 3 Lawrence Berkeley National Laboratory, University of California, Berkeley, California, United States of America

Abstract

The proliferation and terminal differentiation of erythroid progenitors occurs in human bone marrow within erythroblastic islands, specialised structures consisting of a central macrophage surrounded by developing erythroid cells. Many cell-cell and cell-matrix adhesive interactions maintain and regulate the co-ordinated daily production of reticulocytes. Erythroid cells express only one integrin, α4β1, throughout differentiation, and its interactions with both macrophage Vascular Cell Adhesion Molecule-1 and with extracellular matrix fibronectin are critical for erythropoiesis. We observed that proerythroblasts expressed a broad tetraspanin phenotype, and investigated whether any tetraspanin could modulate integrin function. A specific association between α4β1 and CD81, CD82 and CD151 was demonstrated by confocal microscopy and co-immune precipitation. We observed that antibodies to CD81 and CD82 augmented adhesion of proerythroblasts to Vascular Cell Adhesion Molecule-1 but not to the fibronectin spliceoforms FnIII12-15 and FnIII12-15. In contrast, different anti-CD151 antibodies augmented or inhibited adhesion of proerythroblasts to Vascular Cell Adhesion Molecule-1 and the fibronectin spliceform FnIII12-15 but not to FnIII12-15. These results strongly suggest that tetraspanins have a functional role in terminal erythropoiesis by modulating interactions of erythroblast α4β1 with both macrophages and extracellular matrix.

Introduction

In normal human bone marrow, terminal erythroid differentiation occurs within erythroblastic islands [1]. This specialised erythropoietic niche, first described by Bessis [2], comprises a central macrophage surrounded by adherent developing erythroblasts. Within islands, extensive cell-cell interactions occur not only between adjacent erythroblasts, but also between erythroblasts and macrophages, such that each erythroblast is in direct contact with macrophage cellular processes [3]. Some of the molecules involved in these intercellular interactions have been identified (reviewed in [1]). These include: i) macrophage sialoadhesin (CD169, Siglec-1) binding to sialylated erythroblast glycophorin [4], ii) homophilic binding of Erythroblast-Macrophage Protein on both macrophages and erythroblasts [5], iii) macrophage Vascular Cell Adhesion Molecule-1 (VCAM-1) binding to erythroblast α4β1 [6], iv) macrophage αvβ3 integrin binding to erythroblast Intercellular Adhesion Molecule-1 [7], and v) macrophage CD163 (receptor for haemoglobin-haptoglobin complexes) binding to an unidentified erythroblast receptor [8].

The importance of α4β1 during erythropoiesis, and of erythroblast α4β1 interactions with macrophage VCAM-1 has been extensively studied. In vivo administration of anti-α4 antibody rendered mice anaemic [9], while in vitro addition of antibodies reactive with anti-α4 or anti-VCAM-1 antibodies reduced stromal cell-dependent erythropoiesis [10] and disrupted erythroblastic island integrity [6]. Additionally, a requirement for appropriately activated α4β1 for the in vitro reformation of erythroblastic islands has also recently been demonstrated in SWAP-70-deficient mice [11]. SWAP-70, a protein involved in integrin regulation and cytoskeletal F-actin rearrangement, affects development of erythroid progenitors in bone marrow and spleen by negative regulation of α4β1 [11]. In normal human bone marrow, α4β1 is clustered at contact sites between macrophages and erythroblasts [12], and this heterophilic cell contact enhances proliferation [5,13,14]. A role for α4β1 in the optimal expansion and differentiation of erythroid cells in bone marrow, rather than an absolute requirement of α4β1 in erythropoiesis was also evident in α4-null chimeric mice [15]. Studies of the effects on erythropoiesis of α4, β1 or VCAM-1 deficiencies in different mouse models have yielded conflicting results, and demonstrated...
different effects in bone marrow and splenic erythropoiesis [15–20]. However while conditional knockout mice were not anaemic, a role for α4 and β1 but not for VCAM-1 has been demonstrated in stress erythropoiesis with defects in erythroid progenitor expansion in bone marrow and/or spleen, and in cell maturation [11,10–20].

The continued expression of α4β1, the only integrin expressed throughout terminal erythroid maturation [21,22], suggests that interactions within erythroblastic islands between erythroblast α4β1 and its ligands, macrophage VCAM-1 and fibronectin [23], are both important for effective erythropoiesis. The early erythroid progenitors, BFU-E and CFU-E, and proerythroblasts, adhere to fibronectin via both integrins α2β1 and α5β1 [21,24,25]. Whereas α2β1 expression is lost on basophilic erythroblasts, the continued expression but progressive down-regulation of α4β1 during terminal maturation is accompanied by a progressive decrease in attachment to fibronectin until the reticulocyte stage, where these cells are non-adherent [25]. While fibronectin has only one binding site for α5β1, there are five sites for α4β1, three in alternatively spliced regions [26]. The temporal expression of α2β1 and α5β1 during differentiation and the complex expression of fibronectin spliceforms in adult bone marrow [27] hint at distinct and stage-specific functions for integrin/fibronectin interactions during erythroid proliferation and differentiation. Indeed, fetal liver erythroblast α4β1 interaction with fibronectin is essential for maximal erythroid expansion [28]. The appropriate activation state of α4β1 is also important for α4β1-fibronectin interactions since SWAP-70-deficient BFU-E hyper-adhere to more mature cells, or on attachment to fibronectin spliceforms, FnIII12–15 (H/120) and FnIII12–15 (H/0). CD151 also associates with α4β1 but anti-CD151 could either augment or inhibit proerythroblast adhesion to both VCAM-1 and fibronectin spliceform H/120, but not to H/0. These data strongly suggest that CD81, CD82 and CD151 play an important role during erythropoiesis by modulating the adhesive properties of α4β1.

Materials and Methods

Ethics Statement

Buffy coats, a waste fraction from anonymous donations of platelets by apheresis, were provided with written informed consent for research use in accordance with both the Declaration of Helsinki and with the policy of the National Health Service Blood and Transplant. The research into the mechanisms of in vitro erythropoiesis was reviewed and approved by the Southmead Local Research Ethics Committee 08/05/2008 REC number 08/H0102/26.

All reagents, tissue culture media, growth factors, cytokines and certain antibodies were purchased from Sigma (Poole, Dorset, UK) unless stated otherwise.

Erythroid Cultures

Human CD34+ haematopoietic progenitor cells were isolated from human blood donor mononuclear cells (waste buffy coats, see Ethics Statement) by positive selection using the MiniMACS magnetic bead system (Miltenyl Biotec, Bisley, UK) as described by the manufacturer’s protocol. The isolated CD34+ cells were pooled and cultured at 37°C in a humidified atmosphere of 5% CO2 in air in a 2-stage protocol to induce differentiation along the erythroid lineage following a modified method of Griffiths et al. [42]. CD34+ cells were seeded at 1.5×10⁸/ml in primary medium and maintained at 2×10⁸/ml after day 3. When the first glycoporphin A (GPA)-positive cells appeared (days 5–6) erythroblasts were harvested, washed thrice in Hanks Balanced Salt solution and seeded into secondary culture medium and maintained at 3–8×10⁵/ml. Protocol A used Iscove’s Modified Dulbecco Medium (IMDM) containing 1% (w/v) bovine serum albumin (BSA), 10 µg/ml recombinant human insulin and 200 µg/ml iron saturated human transferrin (“Stemspan SFEM”, Stemcell Technologies SARL). In the first stage of culture (day 0–5 or 6) the IMDM was supplemented with 10 ng/ml recombinant human r(h) Stem Cell Factor (SCF, R & D Systems Europe, Abingdon, Oxfordshire, UK), 3 U/ml Erythropoietin (Epo, Roche Products, Welwyn Garden City, UK), 1 ng/ml rH Interleukin-3 (IL-3, R & D Systems Europe), 1 µl/ml cholesterol-rich lipid mix, 0.1 ng/ml Prograf (Fujsawa, Killorglin, Ireland) and 1 U/ml penicillin and streptomycin. In the second stage (days 5–6 onwards) the primary medium was replaced with Stemspan SFEM supplemented with additional 800 µg/ml iron saturated human transferrin, 3% v/v heat inactivated human male group AB serum, 10 U/ml Epo, 10 ng/ml insulin, 1 mM tri-iodothyronine and 1 U/ml penicillin and streptomycin. Protocol B primary culture medium (days 0–5) comprised IMDM (Source BioScience)
containing 3% male AB serum, 2% foetal bovine serum (HyClone, Fisher Scientific UK Ltd), 200 mg/ml iron-saturated transferrin, 10 ng/ml SCF, 3 U/ml Epo, 1 ng/ml IL-3, 0.1 ng/ml Prograf and 1 U/ml penicillin and streptomycin. Secondary stage medium (day 5 onwards) comprised IMDM, 3% male AB serum, 2% foetal bovine serum, 300 mg/ml iron-saturated transferrin, 3 U/ml Epo, 10 ng/ml insulin, 0.1 ng/ml Prograf and 1 U/ml penicillin and streptomycin. Cultures grown in Protocol B media showed increased proliferation over those grown in Protocol A media.

HEL Cell Line
The human erythroleukemia line, HEL, (ECACC, Salisbury, Wiltshire, UK) was maintained at 3×10^5/ml in Iscove’s Modified Dulbecco’s Medium (IMDM, PAA, Laboratories GmbH, Pasching, Austria) containing 10% foetal bovine serum (Fetal Clone 1, HyClone, Logan, Utah) at 37°C in a 5% CO2 atmosphere.

Flow Cytometry
Antigen expression was analyzed by flow cytometry as described [43]; antibodies used are listed in Table 1. RPE-conjugated isotype negative control antibodies were from eBioscience Ltd (Hatfield, Hertfordshire, UK) and BioLegend UK Ltd (Cambridge, Cambridgeshire, UK). Secondary antibody RPE F(ab’)2 goat anti-mouse IgG Fe-specific was from Dako Cytomation (Glossox, UK). After labelling the cells were fixed in phosphate buffered saline (PBS) containing 1% (v/v) BSA (Lorne Laboratories, Reading, Berkshire, UK) and 1% w/v paraformaldehyde then analysed on a FC500 flow cytometer using Kaluza software (Beckman Coulter (UK) Ltd, High Wycombe, Buckinghamshire, UK).

Confocal Microscopy
Cells (3×10^5 cells per coverslip) were seeded on 0.01% (w/v) poly-L-lysine coated coverslips and incubated for 30 minutes at 37°C in 5% CO2. Cells harvested from culture on days 5 to 10 were fixed with 3% paraformaldehyde (TAAB, Aldermaston, UK) for 20 minutes and permeabilised with 0.05% (w/v) digitonin (Merck Millipore, Beaconsfield, Buckinghamshire, UK) for 5 minutes, then incubated for 15 minutes in 4% BSA (Park Scientific, Northampton, Northamptonshire, UK). Subsequent washes were carried out in PBS. Cells harvested from culture from day 11 onwards were fixed in 1% paraformaldehyde and permeabilised in 0.05% saponin (Merck Millipore). Subsequent washes and antibody dilutions were carried out in PBS containing 0.005% saponin, 5 mg/ml BSA and 1 mg/ml glucose. When dual labelling with two monoclonal primary antibodies the first antibody was subjected to an extra conversion step by the addition of AfinilPure Fab fragment rabbit anti-mouse IgG (Jackson ImmunoResearch, Stratach Scientific Ltd, Newmarket, Suffolk, UK) at a concentration of 1/20 in 4% BSA. After this conversion step the secondary monoclonal antibody was added. Primary antibodies used are listed in Table 1. Goat anti-mouse Alexa fluor® 488 or goat anti-rabbit Alexa fluor® 546 (Invitrogen, Carlsbad, California, USA) conjugated secondary antibodies were diluted in 4% normal goat serum and incubated with the cells for 30 minutes at room temperature in the dark. Coverslips were mounted on Vectashield® Mounting Medium (Vector Laboratories, Burlingame, California, USA) on microscope slides and sealed with nail varnish. Samples were imaged at 22°C using 40× oil immersion lenses (magnification = 101.97 μm at zoom 3.8, numerical aperture 1.25) on a Leica SP5 confocal imaging system. Images were obtained using Leica software and subsequently processed using Adobe Photoshop.

Immune Precipitation, SDS-PAGE and Immunoblotting
Cells were washed thrice in 10 mM Tris, 150 mM NaCl, pH 7.4 (TBS), containing either 2 mM ethylenediaminetetraacetic acid (EDTA), 1 mM CaCl2 plus 1 mM MgCl2 or 1 mM MnCl2 (TBS +/- cations/EDTA) by centrifugation at 400 g for 5 minutes at 4°C. The cell pellet was lysed for 25 minutes on ice in lysis buffer (TBS +/- cations or 2 mM EDTA, 1% (w/v) polyoxyethylene (10) oleyl ether (Brij-97), 2 mM phenyl methyl sulphonyl fluoride (PMSE) and EDTA-free protease inhibitor cocktail (Complete™, Roche Diagnostic GmbH, Mannheim, Germany). In some experiments polyoxyethylene (20) oleyl ether (Brij-99), Triton X-100 (TX-100), Nonidet P40 (NP40) or 3-[3-cholamidopropyl]dimethylammonio]-1-propanesulphonic hydrate (CHAPS) were also used at 1% w/v in place of Brij-97. Cells were solubilised at 10^7/ml for HEL cells and proerythroblasts (days 5-6 of culture), 1.5×10^7/ml for basophilic erythroblasts (days 7-8 of culture) and 3×10^7/ml for polychromatophilic erythroblasts (days 11-12 of culture), centrifuged at 208,000 g for 30 minutes at 4°C and the supernatants were stored at −80°C. Immune precipitates were isolated from the cell lysates with antibodies (see Table 2) pre-coupled to Protein G Sepharose 4 Fast Flow (PGS, GE Healthcare Life Sciences, Little Chalfont, Buckinghamshire, UK) after an initial pre-clearing step with Protein G-coupled isotype control antibodies [40]. Immune complexes were eluted into non-reduced sample buffer [44] containing 2 mM PMSE and EDTA-free protease inhibitor cocktail. Samples were run on 7.5% or 12% (w/v) non-reduced polyacrylamide gels. Immunoblotting under semi-dry transfer conditions was as described [7] except that PVDF membranes (Millipore UK Ltd, Watford, Hertfordshire, UK) were blocked with PBS containing 0.8% w/v Tween-20 and 5% w/v γ-globulin-free BSA fraction V. Biotinylated antibodies to CD81 (clone 13.3.2.3, Alexis Corporation, Enzo Life Sciences (UK) Ltd, Exeter, Devon, UK) and rabbit anti-sera to β1, β2 and β3 (R&D Systems, Abingdon, Oxfordshire, UK) were used. Rabbit monoclonal anti-α4 antibody was from Cambridge Bioscience (Cambridge, Cambridgeshire, UK), polyclonal anti-CD82 antibody was from AbCam (Cambridge, Cambridgeshire, UK) and anti-CD53 (MEM-53), anti-CD63 (MEM-259) and anti-CD151 (IG5a) antibodies were from AbD Serotec. Secondary reagents were streptavidin-alkaline phosphatase conjugate (Perkin Elmer, Cambridge, Cambridgeshire, UK) and alkaline phosphatase-conjugated F(ab’)2 fragments of goat anti-sera to rabbit and mouse IgG (Jackson ImmunoResearch). Membranes were developed with Western Lightning CDP Star Chemiluminescent Reagent (Perkin Elmer) and images were recorded on a Kodak imager using Kodak imaging software.

Fusion Proteins
7-domain Vascular Cell Adhesion Molecule-1-Fc fusion protein (VCAM-Fc) was purchased from R&D Systems. Human fibronectin constructs FnIII-a,b,c (H/0) and FnIII-a,b,cIII (H/120), in the PGEX expression vector, were a kind gift from Prof. M. Humphries (University of Manchester) [45]. The constructs were transformed into Rosetta 2(DE3) pLysS E. coli cells (Novagen, Merck Millipore) for expression as previously described [46]. In brief, 10 ml Luria-Bertani (LB) broth cultures with 50 μg/ml carbenicillin and 35 μg/ml chloramphenicol, were inoculated from a glycerol stock and grown overnight at 37°C. 1 L of LB media was inoculated and grown to OD600=0.6. Protein expression was induced by addition of 1 mM isopropyl β-D-1-thiogalactopyranoside at 20°C for 16 h. Cells were harvested by centrifugation, the cell pellet was resuspended in buffer A (50 mM tris pH 8, 150 mM NaCl) supplemented with a protease inhibitor tablet (Roche Diagnostics) and DNAseI. The protein was released...
by sonication and the insoluble fraction pelleted by centrifugation. The supernatant was loaded onto a 5 mL GSTrap FF column (GE Healthcare, Little Chalfont, Buckinghamshire, UK) pre-equilibrated with buffer A. Recombinant protein was eluted by an increasing gradient of buffer B (50 mM tris pH 8, 150 mM NaCl and 10 mM reduced glutathione). The protein was further purified by gel filtration on a HiLoad 16/60 superdex 200 (GE Healthcare) equilibrated in buffer A. Pooled recombinant protein fractions were analysed by SDS-PAGE for 95% purity and confirmed by N-terminal sequencing and mass-spectrometry. Liberation of recombinant human fibronectin H/0 from the glutathione synthase (GST)-tag was accomplished by incubation at 4°C for 20 h with 25 U thrombin. The sample was applied to a GSTrap FF column and benzamidine column (GE Healthcare) in tandem to remove cleaved GST-tag, uncleaved protein and thrombin. Cleaved recombinant H/0 was further purified by gel filtration as above.

Cell Adhesion Assays

Attachment assays were performed essentially as described [47] with modifications. Immulon-4 HBX 96 well plates (DyneX Technologies, Billingshurst, UK) were coated with either 1 μg/ml goat anti-human Fc or anti-GST antibody (AbCam) in bicarbonate buffer overnight at 4°C then incubated with either Fc- or GST-fusion proteins as appropriate overnight at 4°C. Fibronectin H/0 fragment without the GST tag was coated directly onto the plates in PBS. Plates were blocked with PBS containing 4% fraction V BSA. Media for fluorescently labelling cells were either RPMI1640 containing 0.1% BSA (RPMI LB) or IMDM containing 0.1% BSA and 2 mM ethylene glycol tetracetic acid (IMDM LB). Activation of cells with 80 μM phorbol myristate acetate (PMA) was performed at the same time as fluorescence labelling in IMDM LB. Cells were washed after labelling in either RPMI LB or IMDM LB supplemented with additional CaCl2 plus MgCl2 to 1 mM of each, or with 1 mM MnCl2 or 10 mM MgCl2 (assay buffers, AB). Fluorescently labelled cells in AB were added at 2 × 10^5/well for proerythroblasts (day 5 of culture), 2.5 × 10^5/well for basophilic erythroblasts (days 7/8 of culture) and 3 × 10^5/well for polychromatic erythroblasts (days 11–12 of culture). Titration assays had 4 replicates per dilution while 6 replicates were used in antibody activation/inhibition assays. For the latter assays, cells were incubated for 15 mins at room temperature in AB containing 10 μg/ml antibodies before addition to the plates. The plates were coated with proteins at a concentration where just less than maximal cell attachment was obtained. The statistical software package, SigmaPlot12, was used for the one way analysis of variation of results of adhesion assays performed in the presence of added antibodies.

### Table 1. Antibodies used for flow cytometry and confocal microscopy.

| Specificity | RPE-labelled clones | Source | Unlabelled clones | Source |
|-------------|---------------------|--------|------------------|--------|
| CD9         | MM2/57              | AbD Serotec<sup>1</sup> | MM2/57, Gi15   | AbD Serotec<sup>1</sup> Alexis Corporation<sup>2</sup> |
| CD37        | 424925              | R&D Systems<sup>3</sup> | M-B371, NMN-46 | BD Biosciences<sup>4</sup> Invitrogen<sup>5</sup> |
| CD53        | H129 425514         | BioLegend<sup>6</sup> R&D Systems<sup>3</sup> | MEM-53, 65-5A3 | AbD Serotec<sup>1</sup> Alexis Corporation<sup>2</sup> |
| CD63        | MEM-259             | AbD Serotec<sup>1</sup> | MEM-259, HSC6  | AbD Serotec<sup>1</sup> BD Biosciences<sup>4</sup> |
| CD81        | 5A6, 454720         | BioLegend<sup>6</sup> R&D Systems<sup>3</sup> | JS81, 1D6     | BD Biosciences<sup>4</sup> AbD Serotec<sup>1</sup> |
| CD82        | ASL-24, B-2          | BioLegend<sup>6</sup> AbCam<sup>7</sup> | TS82, B-2     | AbCam<sup>6</sup> AbD Serotec<sup>1</sup> |
| CD151       | Ilg5a, 210127       | AbD Serotec<sup>1</sup> R&D Systems<sup>3</sup> | Ilg5a, 210127 | AbD Serotec<sup>1</sup> R&D Systems<sup>3</sup> |
| α4, CD49d   | 44H6, 9F10          | AbD Serotec<sup>1</sup> eBiocience<sup>6</sup> | HP2/1, Max68P | AbD Serotec<sup>1</sup> Dr T Shock<sup>9</sup> |
| α5, CD49e   | 238307, P1D6        | R&D Systems<sup>3</sup> eBiocience<sup>6</sup> | IIA1, JS85    | BD Biosciences<sup>4</sup> AbD Serotec<sup>1</sup> |
| αL, CD11a   | mb38, TS2/4         | AbD Serotec<sup>1</sup> BioLegend<sup>6</sup> | TS1/22, mb38  | ATCC<sup>10</sup> AbD Serotec<sup>1</sup> |
| αLlβ, CD41  | PM6/248, PAB-1      | AbD Serotec<sup>1</sup> eBiocience<sup>6</sup> | PAB-1, SB12   | IBGRL<sup>11</sup> |
| GPA         | BRC256              | IBGRL<sup>11</sup> BRC18, BRC68 | IBGRL<sup>11</sup> IBGRL<sup>11</sup> |
| Kell        | BRIC68              | IBGRL<sup>11</sup> | IBGRL<sup>11</sup> IBGRL<sup>11</sup> |
| AE-1        | BRC6, BRC200        | IBGRL<sup>11</sup> | IBGRL<sup>11</sup> IBGRL<sup>11</sup> |
| Control     | mG1                 | eBiocience<sup>6</sup> | mG1           | Sigma<sup>12</sup> |
| Control     | mG2a                | BD Biosciences<sup>4</sup> | mG2a         | Sigma<sup>12</sup> |
| Control     | mG2b                | AbD Serotec<sup>1</sup> | mG2b         | Sigma<sup>12</sup> |
| Control     | mG3                 | eBiocience<sup>6</sup> | mG3          | Sigma<sup>12</sup> |

<sup>1</sup>AbD Serotec, Oxford, Oxfordshire, UK.
<sup>2</sup>Alexis Corporation, Enzo Life Sciences (UK) Ltd, Exeter, Devon, UK.
<sup>3</sup>R&D Systems, Abingdon, Oxfordshire, UK.
<sup>4</sup>BD Biosciences, Oxford, Oxfordshire, UK.
<sup>5</sup>Invitrogen Ltd, Paisley, UK.
<sup>6</sup>BioLegend Ltd UK Ltd, Cambridge, Cambridgeshire, UK.
<sup>7</sup>AbCam, Cambridge, Cambridgeshire, UK.
<sup>8</sup>eBiocience Ltd, Hatfield, Hertfordshire, UK.
<sup>9</sup>A gift from Dr T Shock, CellTech Chiroscience, Slough, UK.
<sup>10</sup>American Type Culture Collection USA.
<sup>11</sup>IBGRL Research Products, Bristol, UK.
<sup>12</sup>Sigma, Poole, Dorset, UK.

doi:10.1371/journal.pone.0062654.t001
Results

Tetraspanin and Integrin Expression during Erythropoiesis

In our 2-stage cultures 100% of cells expressed the Kell glycoprotein (Kell) by day 3, glycophorin A (GPA) first appeared about day 5 while the erythroid anion exchanger-1 (AE1) was expressed after day 7 (Figure 1A), consistent with the temporal expression of these proteins [48]. The cultures were synchronous at day 5 comprising 90–95% proerythroblasts, predominantly (80%) basophilic erythroblasts on day 8, and a mixed population of polychromatic and orthochromatic erythroblasts, with a minority of reticulocytes and free nuclei by day 12 (Figure 1A). We looked at the expression of 7 haematopoietic tetraspanins in these cultures and observed that from day 3, when all cells expressed Kell, until the first appearance of GPA (around day 5), approximately 45% of cells expressed CD9 whereas all cells were positive for CD37, CD53, CD63, CD81, CD82 and CD151. This tetraspanin profile is similar to that reported for CD34+ cells and the leukaemic proerythroblast cell line, HEL [49,50]. At later stages of maturation, CD9 was down-regulated first (almost negative by day 8, basophilic erythroblasts), followed by CD37 and CD53 (negative by day 12, polychromatic erythroblasts), and lastly, CD63 and CD81 (weaker expression by day 12). CD82 and CD151 were still expressed on day 12, consistent with their continued expression at low levels on mature erythrocytes [51,52]. Throughout erythroid maturation CD82, and to a lesser extent CD81, consistently showed the highest levels of expression of all tetraspanins.

Table 2. Source, epitope location and functional properties of antibodies used for immune precipitation and adhesion assays.

| Specificity | Clone | Source | Epitope | Functional effects |
|------------|-------|--------|---------|-------------------|
| CD37       | NMN46 | Invitrogen\(^1\) |         |                   |
| CD53       | MEM-53 | AbD Serotec\(^2\) | 1       |                   |
| CD53       | 63-5A3 | Alexis Corp\(^3\) | 1       |                   |
| CD53       | H29   | BD Bioscience\(^4\) | Carbohydrate | Yes |
| CD63       | MEM-259 | AbD Serotec\(^2\) |         |                   |
| CD63       | H5C6  | BD Bioscience\(^4\) | 1       |                   |
| CD63       | TEA3/18 | Abnova\(^5\) | 1       | Yes |
| CD81       | 1D6   | AbD Serotec\(^2\) | A       | Aggregating |
| CD81       | JS81  | BD Bioscience\(^4\) | C       | Non-functional |
| CD81       | 454720 | R&D Systems\(^6\) |         |                   |
| CD81       | 3.3.1.2 | Alexis Corp\(^3\) |         |                   |
| CD82       | TS82b | AbCam\(^7\) |         |                   |
| CD82       | 53H5  | eBioscience\(^8\) |         | T cell activation |
| CD82       | 423524 | R&D Systems\(^6\) |         |                   |
| CD82       | ASL-24 | BioLegend\(^9\) |         |                   |
| CD82       | B-L2  | AbD Serotec\(^2\) |         |                   |
| CD151      | IIG5a | AbD Serotec\(^2\) |         |                   |
| CD151      | 50-6  | eBioscience\(^8\) |         | Blocks in vivo metastasis |
| CD151      | 210127 | R&D Systems\(^6\) |         |                   |
| α1, CD29   | TS2/16 | ATCC\(^10\) | βA domain, \(\alpha 207-218\) | Activating |
| α1, CD29   | mab13  | BD Bioscience\(^4\) | βA domain, \(\alpha 207-218\) | Blocking |
| A4, CD49d  | HP2/1  | AbD Serotec\(^2\) | β propeller, 3\(^{rd}\) repeat, \(\alpha 195-268\) | Blocking |
| A5, CD49e  | IIA1   | BD Bioscience\(^4\) |         | Blocking |
| αL, CD11a  | TS1/22 | ATCC\(^10\) | \(\alpha A\) domain | Blocking |
| sLlb, CD41 | PAB-1  | IBGRL\(^{11}\) |         |                   |
| Controls   | Murine | Sigma\(^{12}\) |         |                   |
| Controls   | Rat    | eBioscience\(^8\) |         |                   |

\(^1\)Invitrogen, Paisley, UK.  
\(^2\)AbD Serotec, Oxford, Oxfordshire, UK.  
\(^3\)Alexis Corporation, Enzo Life Sciences (UK) Ltd, Exeter, Devon, UK.  
\(^4\)BD Biosciences, Oxford, Oxfordshire, UK.  
\(^5\)Abnova, Novus Europe Ltd, Cambridge, Cambridgeshire, UK.  
\(^6\)R&D Systems, Abingdon, Oxfordshire, UK.  
\(^7\)AbCam, Cambridge, Cambridgeshire, UK.  
\(^8\)eBioscience Ltd, Hatfield, Hertfordshire, UK.  
\(^9\)BioLegend UK Ltd, Cambridge, Cambridgeshire, UK.  
\(^10\)American Type Culture Collection USA.  
\(^11\)IBGRL Research Products, Bristol, UK.  
\(^12\)Sigma, Poole, Dorset, UK.

doi:10.1371/journal.pone.0062654.t002

CD81 and CD82 Augments \(\alpha 4\beta 1/VCAM-1\) Binding
Erythroblasts also showed developmentally regulated expression of 4 integrins (Figure 1B), consistent with previous reports [21,22,53]. High levels of \( \alpha_4 \) were found throughout the culture period (days 3–12), with lower levels of \( \alpha_5 \), \( \alpha_L \) and \( \alpha_{IIb} \) at the early stages of culture (days 3–5). There was no or very weak expression of \( \alpha_V \) or other \( \beta_1 \) family integrins after day 5 (data not shown). It is interesting to note that early GPA-negative erythroid cells (pre-proerythroblasts and proerythroblasts) express four integrins (\( \alpha_4 \), \( \alpha_5 \), \( \alpha_L \) and \( \alpha_{IIb} \)) and their full complement of 7 tetraspanins (CD9, CD37, CD53, CD63, CD81, CD82 and CD151) while more mature GPA+ erythroblasts express CD81, CD82, CD151 and \( \alpha_4\beta_1 \) and down-regulate expression of other tetraspanins and integrins.

Figure 1. Erythroid culture characterisation and expression of tetraspanins and integrins during terminal maturation. A. Temporal expression of erythroid-specific markers, Kell, GPA and AE1 and morphology of the culture at the same time points. AE1 was tested from day 5 onwards. B. Tetraspanin and integrin profile of the same cultures as shown in A. Results are depicted from one culture where directly conjugated antibodies were used (days 3 and 4) and a second culture with indirectly labelled antibodies (day 5 onwards). The y-axis scale is linear to 350 counts; the x-axis is logarithmic to \( 10^4 \). Images were captured on a Leica DM750 microscope, x20 magnification, using Image-Pro Express 6.0 software. doi:10.1371/journal.pone.0062654.g001
CD81 and CD82 Colocalise with α4β1 throughout Erythroid Maturation

To explore whether CD81 and/or CD82 associate with α4β1 during erythropoiesis, we performed dual immunofluorescence staining of α4 and β1 subunits with these tetraspanins at 3 time points during terminal differentiation (days 5, 8 and 12, proerythroblasts to reticulocytes). We also examined colocalisation with CD63, which is not reported to be associated with α4β1 but is found released in exosomes with α4β1, and with CD151 which is expressed on red cells [51]. CD151 was not pursued as the antibody clone was poor by immunofluorescence and only showed internal staining on day 6 (Figure S1) and became progressively weaker as the cells matured (data not shown). α4 colocalised with β1 at the cell surface at all 3 time points, although the distribution of colocalisation changed as the cells matured (Figure 2A). On day 5 (proerythroblasts), α4 and β1 were present together in small discrete microdomains; by day 8 (basophilic erythroblasts) these areas of colocalisation appeared to coalesce into larger aggregates less evenly spread over the cell surface; by day 12 (polychromatic and orthochromatic erythroblasts) these large aggregates were still evident with stronger staining of tetraspanins in intererythroblast interactions within erythroblastic islands.

CD81 and CD82 Augments α4β1/VCAM-1 Binding

We also showed a very strong association between CD151 and α4β1 during terminal erythroid maturation. α4 and β1-binding sites, in domains one and four. We used two integrins by anti-CD151 antibodies and CD82 staining more abundant than CD81 (Figure 3B). Only at the reticulocyte stage was CD63 also found colocalised at the cell surface with both α4 and β1 on day 12, although usually in one large vesicle (Figure 3B). We hypothesise that these α4β1-positive vesicles coated with CD63, CD81 and CD82 are about to be released from early reticulocytes as exosomes [42], resulting in the loss of the majority of CD63, CD81 and α4β1 and a proportion of CD82. This is consistent with the removal of murine β1 by the exosome pathway [54] and findings that low levels of CD82 but not α4β1, CD63 or CD81 are present on mature erythrocytes [52].

We also observed some colocalisation of CD81 and CD82 in small discrete and unevenly distributed cell surface microdomains in day 6 proerythroblasts (Figure 2B). This pattern of colocalisation differed from the more even distribution of the α4β1–CD81 and α4β1–CD82 complexes described above. Interestingly, colocalisation of CD81 with CD82 was particularly evident at areas of cell contact, suggesting the involvement of tetraspanins in intererythroblast interactions within erythroblastic islands.

Vascular Cell Adhesion Molecule-1 and Fibronectin Fragment FnnIII12-CSIII-15 are High Affinity Ligands for α4β1 while Binding to Low Affinity Fibronectin Fragment FnnIII12-15 is Optimal in Activated Basophilic Erythroblasts

To explore the interaction of α4β1 with VCAM-1 and fibronectin throughout terminal maturation, we performed static adhesion assays using several different integrin activating ligands. The 7-domain VCAM-1 construct contains two α4β1-binding sites, in domains one and four. We used two fibronectin spliceforms found in human bone marrow [27], FnnIII12-CSIII-15 (H/0) and FnnIII12-CSIII-15 (H/120). H/0 is the lowest affinity ligand for α4β1 [55] and consists of a PRARI motif in the B-C loop of domain 14 [45]. H/120 has three α4β1 attachment sites, the PRARI motif and two sites in the complete alternatively spliced IIICS domain, inserted between domains 14 and 15 [26]. Within this IIICS domain the highest
Figure 2. Confocal imaging of erythroblasts. A. (A) Dual staining of \( \alpha 4 \) (red) and \( \beta 1 \) (green) (top panel) and of tetraspanins CD63, CD81 and CD82 (all green) with \( \alpha 4 \) and \( \beta 1 \) integrins (both red) on days 5, 8 and 12 of culture. Colocalisation is seen in yellow on the coloured images and the adjacent grayscale images highlight yellow areas of colocalisation only (scale bars = 10 µm). (B) Cell surface staining of CD81 (red) and CD82 (green) on day 6 erythroblasts shown in fluorescence and phase contrast. Colocalisation is seen in yellow on the both the coloured and phase images (scale bars = 10 µm).

doi:10.1371/journal.pone.0062654.g002
affinity site in the CS1 region comprises the LDV motif, while the REDV motif in the CS5 region has a lower affinity for \( \alpha 4 \beta 1 \). VCAM-1 supported high levels of cell attachment at a 10-fold lower coating concentration than H/120 and H/0 under all activating conditions at the three time points (Figure 5) suggesting that VCAM-1 was the highest affinity ligand for erythroblasts at all stages of maturation. H/120 also supported similarly high maximal levels of cell attachment at all stages of maturation. The lowest levels of adhesion to both VCAM-1 and H/120 were seen with physiological concentrations of Ca\(^{2+}\) with Mg\(^{2+}\) at the proerythroblast (ProEB, day 5) and polychromatic (PolyEB, day 11) stages. Activation with either Mn\(^{2+}\) or with PMA plus Mg\(^{2+}\) increased the affinity of attachment to both ligands at both time points. In contrast, adhesion of cells at the basophilic stage (BasoEB, day 7) differed from other time points since there was little difference in the binding affinity of cells to VCAM-1 and H/120 in the presence of Ca\(^{2+}\) and Mg\(^{2+}\), or with Mn\(^{2+}\), while lower affinity binding was evident after activation with PMA plus Mg\(^{2+}\). H/0, when captured as a GST-fusion protein, did not support erythroblast adhesion at any time point (data not shown) although low levels of attachment were evident when the protein without the GST tag (pure H/0) was coated directly onto the plate (Figure 5). This suggests that a specific conformation of H/0 is required for cell attachment, which is not maintained in the H/0-GST fragment. While pure H/0 did not support more than 20% of input cell binding under any activating conditions at the proerythroblast and polychromatic stages (days 5 and 11), different results were again obtained with basophilic stage cells (day 7). Although activation by PMA plus Mg\(^{2+}\) had a minor effect on cell attachment, Mn\(^{2+}\) greatly increased the binding affinity of basophilic cells to pure H/0. The diverse effects of the different integrin activation conditions on basophilic erythroblast attachment to the three \( \alpha 4 \beta 1 \) ligands strongly suggests that the integrin undergoes developmentally regulated changes that alter its ligand binding profile during terminal maturation.

Figure 3. Confocal imaging of reticulocytes. A. (A) Dual staining of tetraspanins CD63, CD81 and CD82 (all green) with \( \alpha 4 \beta 1 \) integrins (both red) on day 12 of culture shown in phase contrast and fluorescence (scale bars = 10 \( \mu m \)). Colocalisation is seen in yellow. (B) Single examples of reticulocytes zoomed in from images in (A) shown in phase contrast, fluorescence and greyscale images. Yellow on phase contrast and fluorescence denotes colocalisation. The righthand greyscale images highlight yellow areas of colocalisation only (scale bars = 5 \( \mu m \)).

doi:10.1371/journal.pone.0062654.g003

CD81 and CD82 Augments \( \alpha 4 \beta 1/VCAM-1 \) Binding
Figure 4. Tetraspanins CD81, CD82 and CD151 are associated with α4β1 throughout erythroid maturation and with β3 in proerythroblasts and basophilic erythroblasts. A. CD81, CD82 and CD151 precipitates from Mn²⁺-activated proerythroblasts (ProEB, day 5), basophilic (BasoEB, day 8) and polychromatic (PolyEB, day 12) erythroblasts were successively probed with anti-α4, anti-β1 and anti-β3 antibodies; tetraspanin controls from each time point are also illustrated. All tetraspanins co-precipitated α4 and β1 from erythroblasts B. Tetraspanin precipitates CD81 and CD82 Augments α4β1/VCAM-1 Binding.
Anti-CD81 and Anti-CD82 Antibodies have a Pro-adhesive Effect on Proerythroblast Adhesion to Vascular Cell Adhesion Molecule-1 while an Anti-CD151 Antibody Augments Proerythroblast Adhesion to both Vascular Cell Adhesion Molecule-1 and Fibronectin Fragment FnIII12-CSIII-15.

Using static adhesion assays we investigated whether adhesion of erythroblasts to VCAM-1, H/120 and H/0 in physiological concentrations of Ca\(^{2+}\) and Mg\(^{2+}\) was affected by anti-tetraspanin antibodies. Attachment to both VCAM-1 and H/120 was augmented by 108–127% in the presence of the β1-activating mAb, TS2/16, and was lowest on basophilic erythroblasts (118% and 108% respectively, BasoEB, Figure 6).

Adhesion to both ligands was inhibited to a certain degree by the anti-β1-inhibitory mab 13 antibody at the 3 time points tested although inhibition was less marked on basophilic erythroblasts, and more effective against VCAM-1 than against H/120 (93%, 82% and 93% inhibition as compared to 54%, 18% and 54% inhibition, respectively, Figures 6, S5, S6). Neither anti-β1 antibody affected the low levels of attachment to H/0 in the presence of Ca\(^{2+}\) and Mg\(^{2+}\) at any time point from day 6 proerythroblasts (ProEB) solubilised in the presence of EDTA or different cations, and from Mn\(^{2+}\)-activated basophilic erythroblasts (BasoEB, day 8) were probed with a mix of antibodies to α5, β1, β2 and β3 integrins while the control samples were probed with the relevant tetraspanin antibodies. For clarity, integrin controls are illustrated for the EDTA blot but were present on all blots. β1 and β3 integrins were precipitated well only in the presence of Mn\(^{2+}\). C. CD81 and CD82 precipitates from day 5 proerythroblasts were successively probed with different anti-integrin subunit antibodies and demonstrate co-precipitation of β1 and β3 but not α5 or β2 integrins. D. CD81 (454720) and CD82 (53H5) precipitates from day 6 proerythroblasts (ProEB) and HEL cells (HEL) solubilised in the presence of EDTA, Ca\(^{2+}\)+Mg\(^{2+}\) or Mn\(^{2+}\) probed with anti-CD82 and anti-CD81 antibodies. Each tetraspanin co-precipitates the other most strongly in the presence of Mn\(^{2+}\) from proerythroblasts while any cation permits co-precipitation in HEL cells. Integrins were analysed on 7.5% gels, tetraspanins on 12% gels; non-reducing conditions. Unless stated, the following clones were used: CD53, MEM-53; CD63, MEM-259; CD81, 454720; CD82, TS82b; CD151, IIG5a; α4, HP2/1; α5, IIA1; αL, TS1/22; αIIb, PAB-1. All day 5 and 6 cultures comprised 90–95% proerythroblasts; day 8 culture comprised 5% proerythroblasts, 81% basophilic erythroblasts and 14% polychromatic erythroblasts; day 12 culture comprised 41% polychromatic erythroblasts, 15% orthochromatic erythroblasts and 41% reticulocytes. In the day 5 and 6 cultures 15–34% of cells were GPA+ and 28–35% of cells were αIIb+. Day 8 and day 12 cultures had 77% and 97% GPA+ cells, respectively, and 9% and 0% αIIb+ cells, respectively.

doi:10.1371/journal.pone.0062654.g004

Figure 5. Effect of different activation conditions on erythroblast α4β1 attachment to Vascular Cell Adhesion Molecule-1 and Fibronectin fragments, H/120 and H/0. Erythroblasts were allowed to attach to dilutions of VCAM-1, H/120 and H/0 in the presence of different cations to activate α4β1. γ, 1 mM Ca\(^{2+}\) plus 1 mM Mg\(^{2+}\); ■, 1 mM Mn\(^{2+}\); ▲, 80 μM PMA plus 10 mM Mg\(^{2+}\). Day 5 cells (proerythroblasts, ProEB) were from one culture while days 7 (basophilic erythroblasts, BasoEB) and 11 (polychromatic erythroblasts, PolyEB) cells were from a second culture which was also used for the assays depicted in (Fig. 6) on subsequent days. Each data point is the mean of 4 replicates with the ± standard deviation error bars shown. Readings in excess of 100% input cells bound were only evident in day 11 cells. High levels of haemoglobin within the cells quenches the fluorescence of the initial 100% input cells bound reading, and is evident with highly activated cells; this artefact does not occur with non-haemoglobinised day 5 cells.

doi:10.1371/journal.pone.0062654.g005
Coated at 0.2 mg/ml on 4 occasions). The pre-coating concentrations of VCAM-1 and H/120 allowed slightly less than maximal cell attachment. VCAM-1 was pre-

Figure 6. Effect of anti-tetraspanin antibodies on erythroblast attachment to Vascular Cell Adhesion Molecule-1 and fibronectin fragment H/120. Attachment of erythroblasts to ligand in the presence of 1 mM Ca\(^{2+}\) plus 1 mM Mg\(^{2+}\) and 10 \(\mu\)g/ml of isotype control, inhibitory or activating anti-\(\beta1\) and anti-tetraspanin antibodies. Each data point is the mean of 6 replicates, each expressed as the percentage of the average of the relevant isotype control cells bound (the normalised values); standard deviations are shown, calculated from the normalised values. The results depicted are from the same culture at 3 time points (ProEB, day 5; BasoEB day 8; PolyEB, day 12) and are representative results of the series of data collected. *, P < 0.001; **, P < 0.050; ***, P = 0.050–0.055 compared with the relevant isotype control values as determined by one way analysis of variation. Box-Whisker plots of the complete series of experiments performed with CD81, CD82 and CD151 clones with both ligands, with statistically significant results highlighted, are depicted in Figures S5 and S6. Altogether 6 cultures were assayed (days 5 and 8 were performed on 5 occasions, day 12 on 4 occasions). The pre-coating concentrations of VCAM-1 and H/120 allowed slightly less than maximal cell attachment. VCAM-1 was pre-coated at 0.2 \(\mu\)g/ml, 0.125 \(\mu\)g/ml and 0.25 \(\mu\)g/ml while H/120 was pre-coated at 2 \(\mu\)g/ml, 1.25 \(\mu\)g/ml and 1 \(\mu\)g/ml for proerythroblasts (ProEB, black bars, day 5); basophilic erythroblasts (BasoEB, grey bars, day 8) and polychromatic erythroblasts (PolyEB, white bars, day 12) respectively. Readings in excess of 100% input cells bound were sometimes evident in haemoglobinised cells (days 8 and 12). High levels of haemoglobin within the cells quenches the fluorescence of the initial 100% input cells bound reading, and was evident only with day 12 cells in this assay (all the H/120 results and only the VCAM-1 with T52/16 result); this artefact does not occur with non-haemoglobinised day 5 cells. Day 5 culture comprised 5% pre-erythroblasts, 91% proerythroblasts and 4% basophilic erythroblasts (28% GPA\(^a\)+); day 8 culture comprised 11% proerythroblasts, 60% basophilic erythroblasts and 28% polychromatic erythroblasts (88% GPA\(^a\)+); day 12 culture comprised 15% basophilic erythroblasts, 48% polychromatic erythroblasts, 15% orthochromatic erythroblasts and 21% reticulocytes (99% GPA\(^a\)+).

Our report is the first detailed description of the tetraspanin profile of primary human erythroblasts. Proerythroblasts expressed seven tetraspanins concomitantly with four integrins, while more differentiated cells expressed only \(\alpha 4\beta 1\) together with tetransins CD81, CD82 and CD151, all of which are known to associate with \(\alpha 4\beta 1\) in other haemopoietic cells, including CD34+ and HEL cells [39–41,56,57]. Confocal imaging demonstrated the cell surface colocalisation of discrete pools of \(\alpha 4\beta 1\) with both CD81 and CD82, and of CD81 with CD82 throughout differentiation. The distribution of the cell surface \(\alpha 4\beta 1\)-CD81-CD82 micro-domains changed with increasing erythroblast maturation, suggesting a reorganisation of proteins within the plasma membrane. As the cells matured these complexes appeared to amalgamate, becoming fewer but larger in size. Evidence for an \(\alpha 4\beta 1\)-CD81-CD82 complex throughout late stage maturation was also demonstrated by co-precipitation. Protein association was dependent on the presence of divalent cations, particularly Mn\(^{2+}\), an observation not reported for other cells [39,58,59]. Our data

Discussion

(data not shown), despite evidence for increased integrin affinity induced by Mn\(^{2+}\) at the basophilic stage (BasoEB, figure 5).

Two anti-CD82 antibodies (423524 and TS82) and the anti-CD81 antibody 1D6 (epitope A), but not other anti-CD81 antibodies [JS81 (epitope B) and 454720] augmented proerythroblast adhesion to VCAM-1 by 115–125%, a similar level to 

Other anti-tetraspanin antibodies to CD151 (210127), CD37 (MMN46), CD53 (63-5A5) and CD63 (TEA3/18, MEM-259) had minimal effects on adhesion to VCAM-1, H/120 or H/0 at any time point (Figure 6 and data not shown).

Two anti-CD82 antibodies (423524 and TS82) and the anti-CD81 antibody 1D6 (epitope A), but not other anti-CD81 antibodies [JS81 (epitope B) and 454720] augmented proerythroblast adhesion to VCAM-1 by 115–125%, a similar level to 

Other anti-tetraspanin antibodies to CD151 (210127), CD37 (MMN46), CD53 (63-5A5) and CD63 (TEA3/18, MEM-259) had minimal effects on adhesion to VCAM-1, H/120 or H/0 at any stage of maturation (H/120, Figures 6, S5 and data not shown). We also observed effects with anti-CD151 antibodies on adhesion to VCAM-1 and H/120 but not to H/0. The functional clone, 50-6, augmented proerythroblast adhesion to both VCAM-1 and H/120, whilst a minor inhibitory effect on VCAM-1 binding was also seen with IIg5a at all stages of erythroid maturation (Figures 6, S5, S6). Other anti-tetraspanin antibodies to CD151 (210127), CD37 (MMN46), CD53 (63-5A5) and CD63 (TEA3/18, MEM-259) had minimal effects on adhesion to VCAM-1, H/120 or H/0 at any time point (Figure 6 and data not shown).
suggest that more stable α4β1-CD81-CD82 microdomains assemble when erythroblast α4β1 is in a highly activated state. We also demonstrated that the association of CD81 and CD82 with α4β1 was functionally significant, since antibodies to both tetraspanins augmented proerythroblast adhesion to VCAM-1 in the presence of physiological concentrations of Ca²⁺ with Mg²⁺. We did not use Mn²⁺ in these assays as it has recently been suggested that augmentation effects of tetraspanins on integrin affinity are only evident in systems where conditions are not optimal [50]. There is little evidence for effects of tetraspanin antibodies on the affinity of integrin-mediated adhesion to ligands in static adhesion assays in other cells [29], or on integrin-extracellular matrix protein interactions [37]. Instead, effects are mainly seen in post-ligand binding events, and are evident in integrin-dependent cell spreading, motility and morphology [29,35,37]. In this context CD81 enhanced α4β1-mediated adhesion strengthening to stromal cell fibronectin [60] and to VCAM-1 under shear flow [61]. Similarly, CD9 induced pre-B cell adhesion to bone marrow fibroblast-bound fibronectin by up-regulating the avidity of α4β1 and α5β1 [62]. Our data suggest that CD81 and CD82 can increase the affinity of α4β1 for VCAM-1 perhaps by promoting receptor clustering. The functional effects of the anti-tetraspanin antibodies suggest that both tetraspanins modulate proerythroblast-macroage interactions.

Tetraspanin CD151 was also physically and functionally associated with α4β1, irrespective of activation state, in contrast to CD81 and CD82. Different anti-CD151 antibodies also had consistently different functional effects not only on adhesion to VCAM-1, but also to the fibronectin H/120 fragment. Similar to data obtained for tetraspanins CD81 and CD82, the pro-adhesive effect was again evident at the proerythroblast stage of maturation. While the ability of CD151 to regulate integrin-mediated adhesion strengthening in other cells has been extensively studied [35], this is the first report of an effect on α4β1-mediated adhesion. Our data suggest that tetraspanin CD151 also modulates α4β1-mediated erythroblast binding not only to macroages, but also to fibronectin, the latter finding also seen in HEL cells [40]. These observations suggest that CD151 could modulate early proerythroblast interactions with several ligands. Indeed, minor effects of CD151 on erythropoiesis have been noted in both CD151-null individuals and one mouse model [51,63]. CD151 may also be important for megakaryopoiesis since anti-CD151 decreases megakaryocyte progenitor generation in stromal cell cultures [57]. We also observed that tetraspanins CD81, CD82 and CD151 were associated with activated β3 integrins in primary and leukemic erythroblasts, suggesting that these proteins may similarly also modulate early proerythroblast-fibronectin interactions, perhaps affecting erythroid progenitor proliferation and/or differentiation.

We found that the ligand preference for erythroid α4β1 is VCAM-1> H/120 > H/0, and this high affinity interaction with VCAM-1 is similar to other haematopoietic cells [64,65]. The activation states attainable by α4β1 and its ligand profile are cell type-specific and regulated by unknown factors [64]. Moreover, functionally distinct pools of α4β1 exist together in the membrane, the low affinity pool regulating α4β1-mediated adhesion [65]. Several of our observations also suggested a developmentally regulated alteration in ligand binding and in the activation states attainable by α4β1 in erythroid cells (Figure 5). There was a change in adhesion to H/0 and only basophilic erythroblast attachment to H/0 was activated by Mn²⁺, with no effect on proerythroblast or polychromatic stage cells (Figure 5). Similarly the different cations activated basophilic erythroblast attachment to VCAM-1 and H/120 to the same extent, in contrast to the differences seen with these cations on proerythroblast and polychromatic erythroblast attachment. Furthermore, there was a reduced ability of mab 13 to inhibit basophilic erythroblast attachment to H/120 when compared with inhibition of attachment of proerythroblasts and polychromatic erythroblasts (Figure 6, Figure S6). Since mab 13 recognises an epitope that is attenuated by both VCAM-1 and H/120 binding to α4β1 [66], our results suggest that developmentally regulated changes of basophilic erythroblasts α4β1 increase the ability of H/120 to displace mab 13. Our attachment assays suggest that for proerythroblasts and also perhaps for pre-proerythroblasts, the association of α4β1 with CD81, CD82 and CD151 increases the affinity and/or clustering of α4β1 and promotes erythroblast/macrophage interactions, in preference to the erythroblast α4β1-fibronectin interaction. An anti-CD151 antibody also augmented erythroblast-fibronectin interactions, suggesting that the association of CD151 with α4β1 can additionally promote proerythroblast-extracellular matrix interactions. Our results demonstrate that tetraspanins can modulate specific α4β1-ligand interactions, in contrast to the reported overall general negative regulation of all erythroblast α4β1 ligand interactions by SWAP-70 [11]. Newham et al., [66] have suggested that as different ligands induce different conformational changes in α4β1, ligand-specific signals can be transduced into the cell. In the context of erythroid cells, this could result in different down-stream signalling events after either fibronectin or VCAM-1 engagement, and may promote the effective erythroblast proliferation and differentiation programme when cells attach to macroage VCAM-1 and develop within erythroid blasts.

Supporting Information

Figure S1 CD151 fluorescence in day 6 erythroblasts. CD151 showed internal fluorescence (green) in day 6 erythroblasts but was negative by fluorescent confocal microscopy as the cells matured (data not shown). (TIF)

Figure S2 Several anti-tetraspanin antibodies co-precipitate β1 integrins from HEL cells solubilised in Brij-97. Precipitates were prepared from HEL cells solubilised in different detergents in the presence of Mn²⁺. CD53, MEM-53; CD63, MEM-259; CD81, 454720; CD82, TS82b; CD151, IIG5a; α4, L2, TS1/22; αLβ2, PAB-1. Precipitates were run on 7.5% non-reduced gels. (TIF)

Figure S3 All anti-CD81, anti-CD82 and anti-CD151 clones co-precipitate β1 and β3 integrins from normal and leukemic proerythroblasts. A. CD81 clones. B. CD82 clones. C. CD151 clones. ERB, day 6 proerythroblasts. α4, HP2/1; αL, TS1/22; αLβ2, PAB-1. Integrins in 7.5% NR gels, tetraspanins in 12% non-reduced gels. More β3 integrins are co-precipitated from HEL cells as they express αLβ3 and αVβ3; proerythroblasts express only αLβ3. (TIF)

Figure S4 Co-precipitation of β1 and β3 integrins by tetraspanins with different cations from HEL cells. Precipitates were prepared from HEL cells solubilised in Brij-97 in the presence of EDTA or cations. β1 is co-precipitated by CD63, CD81, CD82 and CD151 while β3 is co-precipitated by all tetraspanins in the presence of Mn²⁺. CD151 co-precipitates β1 under all conditions. Integrins were separated on 7.5% gels, tetraspanin controls on 12% gels, both non-reducing conditions.
concentrations of VCAM-1Fc were 0.2 μg/ml, 0.125 μg/ml and 0.25 μg/ml for ProEB, BasoEB and PolyEB, respectively. *(TIF)*

**Figure S5** Effect of antibodies to β1 and tetraspanins on the binding of erythroblasts to fibronectin fragment FnIII12-1HCS-15. Box-Whisker plots of normalized values (calculated from the average value of isotype control cells bound) of each data point from all experiments performed at three stages of maturation, with the median, 10th, 25th, 75th and 90th percentiles depicted as vertical boxes with error bars. *, P<0.001 compared with the relevant isotype control values for each clone as determined by one way analysis of variance (which is a subset of all control values depicted at each time point). All antibodies were tested at each time point at least three times except for CD82 423524 (twice on days 5 and 8, once on day 12) and CD81 ID6 (three times on day 8, once on day 12) and CD81 JS81 (twice on day 12). Coating concentrations of fibronectin FnIII12-1HCS-15 (H/120) were 2.00 μg/ml, 1.25 μg/ml and 1.00 μg/ml for ProEB, BasoEB and PolyEB, respectively. *(TIF)*

**Figure S6** Effect of antibodies to β1 and tetraspanins on the binding of erythroblasts to fibronectin fragment FnIII12-1HCS-15. Box-Whisker plots of normalized values (calculated from the average value of isotype control cells bound) of each data point from all experiments performed at three stages of maturation, with the median, 10th, 25th, 75th and 90th percentiles depicted as vertical boxes with error bars. *, P<0.001 compared with the relevant isotype control values for each clone as determined by one way analysis of variance (which is a subset of all control values depicted at each time point). All antibodies were tested at each time point at least three times except for CD82 423524 (twice on days 5 and 8, once on day 12) and CD81 ID6 (three times on day 8, once on day 12) and CD81 JS81 (twice on day 12). Coating concentrations of fibronectin FnIII12-1HCS-15 (H/120) were 2.00 μg/ml, 1.25 μg/ml and 1.00 μg/ml for ProEB, BasoEB and PolyEB, respectively. *(TIF)*

**References**

1. Chasin JA, Mohandas N (2008) Erythroblastic islands: niches for erythropoiesis. Blood 112: 470–478.
2. Bessis M (1958) Erythroblastic island, functional unity of bone marrow. Rev Hematol 13: 8–11.
3. Mohandas N, Prentant M (1978) Three-dimensional model of bone marrow. Blood 51: 635–645.
4. Morris L, Crocker PR, Fraser I, Hill M, Gordon S (1991) Expression of a divalent cation-dependent erythroblast adhesion receptor by stromal macrophages from murine bone marrow. J Cell Sci 99: 141–147.
5. Hanspal M, Hanspal JS (1994) The association of erythroblasts with macrophages promotes erythroid proliferation and maturation: a 30-kD heparin-binding protein is involved in this contact. Blood 84: 3494–3504.
6. Sadahira Y, Yoshino T, Monobe Y (1995) Very late activation antigen 4-(VLA-4) vascular cell adhesion molecule 1 interaction is involved in the formation of erythroblastic islands. J Exp Med 181: 411–415.
7. Lee G, Lo A, Short SA, Mankelow TJ, Spring F, et al. (2006) Targeted gene deletion demonstrates that the cell adhesion molecule ICAM-4 is critical for erythroblastic island formation. Blood 108: 2064–2071.
8. Fabriek BO, Polfliet MM, Vloet RP, van der Schors RC, Ligtenberg AJ, et al. (2012) A critical role of VLA-4 in erythropoiesis in vivo. Blood 87: 2531–2537.
9. Yano N, Sekine Y, Yagita H, Ohinata M (1994) Roles for integrin very late activation antigen-4 in stromal-dependent erythropoiesis. Blood 83: 2844–2850.
10. Ripich T, Jesberger R (2011) SWAP-70 regulates erythropoiesis by controlling α3 integrin. Haematologica 96: 1745–1752.
11. Soligo D, Schiro R, Lukch R, Manara G, Quirici N, et al. (1990) Expression of integrins in human bone marrow. Br J Haematol 76: 323–332.
12. Crocker PR, Gordon S (1985) Isolation and characterization of resident stromal macrophages and hematopoietic cell clusters from mouse bone marrow. J Cell Sci 99: 141–147.
13. Hanspal M, Hanspal JS (1994) The association of erythroblasts with macrophages promotes erythroid proliferation and maturation: a 30-kD heparin-binding protein is involved in this contact. Blood 84: 3494–3504.
14. Hanspal M, Hanspal JS (1994) The association of erythroblasts with macrophages promotes erythroid proliferation and maturation: a 30-kD heparin-binding protein is involved in this contact. Blood 84: 3494–3504.
15. Arroyo AG, Yang JT, Rayburn H, Hynes RO (1999) Deletion of αι integrins from adult hematopoietic cells reveals roles in homostasis, regeneration, and homing. Mol Cell Biol 23: 9349–9360.
16. Bunigartz G, Stiller S, Bauer M, Muller W, Schippers A, et al. (2006) Adult murine hematopoiesis can proceed without β1 and β7 integrins. Blood 108: 1587–1594.
17. Ulyanova T, Jiang Y, Padilla S, Nakamoto B, Papayannopoulou T (2011) Combinatorial and distinct roles of α5 and αι integrins in stress erythropoiesis in mice. Blood 117: 975–983.
18. Rosenthal M, Vuillet-Gauger MH, Leroy C, Coulombel L (1991) Coexpression of two fibronectin receptors, VLA-4 and VLA-5, by immature erythroid precursor cells. J Clin Invest 87: 6–11.
19. Papayannopoulou T, Brice M (1992) Integrin expression profiles during erythroid differentiation. Blood 79: 1696–1694.
20. Coulombel L, Auffray I, Gauger MH, Rosenthal M (1997) Expression and function of integrins on hematopoietic progenitor cells. Acta Haematol 97: 13–21.
21. Verfallie CM, McCarthy JB, McGlave PB (1993) Differentiation of primitive human multipotent hematopoietic progenitors into single lineage chonogonic progenitors is accompanied by alterations in their interaction with fibronectin. J Exp Med 174: 693–703.
22. Vuillet-Gauger MH, Breton-Gorius J, Vaimchenker W, Guichard J, Leroy C, et al. (1990) Loss of attachment to fibronectin with terminal human erythroid differentiation. Blood 75: 865–873.
23. Hanpal M, Hanspal JS (1994) The association of erythroblasts with macrophages promotes erythroid proliferation and maturation: a 30-kD heparin-binding protein is involved in this contact. Blood 84: 3494–3504.
24. Schofield KP, Humphries MJ (1999) Identification of fibronectin IIICS variants important for hematopoiesis in vivo. Blood 87: 2531–2537.
25. Ripich T, Jesberger R (2011) SWAP-70 regulates erythropoiesis by controlling α3 integrin. Haematologica 96: 1745–1752.
26. Pankov R, Yamada KM (2002) Fibronectin at a glance. J Cell Sci 115: 3861–3863.
27. Schofield KP, Humphries MJ (1999) Identification of fibronectin IIICS variants important for hematopoiesis in vivo. Blood 87: 2531–2537.
28. Scott LM, Priestley GV, Papayannopoulou T (2003) Deletion of αι integrins from adult hematopoietic cells reveals roles in homeostasis, regeneration, and homing. Mol Cell Biol 23: 9349–9360.
29. Bunigartz G, Stiller S, Bauer M, Muller W, Schippers A, et al. (2006) Adult murine hematopoiesis can proceed without β1 and β7 integrins. Blood 108: 1587–1594.
30. Ulyanova T, Jiang Y, Padilla S, Nakamoto B, Papayannopoulou T (2011) Combinatorial and distinct roles of α5 and αι integrins in stress erythropoiesis in mice. Blood 117: 975–983.
31. Rosenthal M, Vuillet-Gauger MH, Leroy C, Coulombel L (1991) Coexpression of two fibronectin receptors, VLA-4 and VLA-5, by immature erythroid precursor cells. J Clin Invest 87: 6–11.
32. Papayannopoulou T, Brice M (1992) Integrin expression profiles during erythroid differentiation. Blood 79: 1696–1694.
33. Coulombel L, Auffray I, Gauger MH, Rosenthal M (1997) Expression and function of integrins on hematopoietic progenitor cells. Acta Haematol 97: 13–21.
34. Verfallie CM, McCarthy JB, McGlave PB (1993) Differentiation of primitive human multipotent hematopoietic progenitors into single lineage chonogonic progenitors is accompanied by alterations in their interaction with fibronectin. J Exp Med 174: 693–703.
35. Vuillet-Gauger MH, Breton-Gorius J, Vaimchenker W, Guichard J, Leroy C, et al. (1990) Loss of attachment to fibronectin with terminal human erythroid differentiation. Blood 75: 865–873.
36. Pankov R, Yamada KM (2002) Fibronectin at a glance. J Cell Sci 115: 3861–3863.
35. Charrin S, Le NF, Silvie O, Milhiet PE, Bouchex C, et al. (2009) Lateral organization of membrane proteins: tetraspanin spin their web. Biochem J 420: 133–154.

36. Yancez-Mo M, Barreiro O, Gordon-Alonso M, Sala-Valdés M, Sanchez-Madrid F (2009) Tetraspanin-enriched microdomains: a functional unit in cell plasma membranes. Trends Cell Biol 19: 434–446.

37. Hemler ME (2005) Tetraspanin functions and associated microdomains. Nat Rev Mol Cell Biol 6: 801–811.

38. Rubinstein E (2011) The complexity of tetraspanins. Biochem Soc Trans 39: 501–505.

39. Mannion BA, Berditchevski F, Kraeft SK, Chen LB, Hemler ME (1996) Transmembrane 4 superfamily proteins CD9, CD33, CD63, and CD53 specifically associated with integrin alpha[4]beta[1] (CD94/CD29). J Immunol 157: 2039–2047.

40. Fitter S, Sinclair PM, Polliffe CN, Ashman LK (1999) Transmembrane 4 superfamily protein CD151 (PETA-3) associates with alpha[1] and beta[3] integrins in haemopoietic cell lines and modulates cell-cell adhesion. Biochem J 338: 61–70.

41. Serru V, Le NF, Billard M, Azores DO, Lanza F, et al. (1999) Selective tetraspan-integrin complexes (CD81/alpha[4]beta[1], CD151/alpha[3]beta[1], CD51/alpha[6]beta[1]) under conditions disrupting tetraspan interactions. Biochem J 340: 103–111.

42. Griffiths RE, Keppie S, Cogan N, Mankelow TJ, Britin VM, et al. (2012) Maturing reticulocytes internalise plasma membrane in glycoporphin A-containing vesicles which fuse with autophagosomes prior to egress from blood cells. Blood 119: 6296–6306.

43. Smythe JS, Avent ND, Parsons SF, Martin PG, et al. (1996) Expression of RHD and RHCE gene products using retroviral transduction of K562 cells establishes the molecular basis of Rh blood group antigens. Blood 87: 2968–2973.

44. Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature Lond 227: 680–685.

45. Sharma A, Askari JA, Humphries MJ, Jones EY, Stuart DI (1999) Crystal identification of critical amino-acid residues on the erythroid intercellular adhesin UspA1 with fibronectin and receptor CEACAM1 binding. Proc Natl Acad Sci U S A 106: 15174–15178.

46. Vidal M (2010) Exosomes in erythropoiesis. Transfus Clin Biol 17: 131–137.

47. Ashman LK, Fitter S, Sincock PM, Nguyen MT, Cambareri AC (1998) CD151 tetraspanin facilitates instantaneous leukocyte VLA-4 adhesion strengthening to vascular cell adhesion molecule 1 (VCAM-1) under shear flow. J Biol Chem 273: 51203–51212.

48. Royston CM, White MM, Wilkinson DA, Jennings LK (1999) A CD9, beta[3] integrin-associated protein, and GPIb/VI/IX complex on the surface of human platelets is influenced by alpha[IIb]beta[3] conformational states. Eur J Biochem 263: 104–111.

49. Yancez-Mo M, Mittelbrunn M, Sanchez-Madrid F (2001) Tetraspanins and intercellular interactions. Microcirculation 8: 153–168.

50. Behr S, Schiefer F (1995) Engaging CD19 or target of an anti-proliferative antibody 1 on human B lymphocytes induces binding of B cells to the integrians. J Exp Med 182: 1199–1199.

51. Wright MD, Geary SM, Fitter S, Moseley GW, Law LM, et al. (2004) Characterization of mice lacking the tetraspanin superfamily member CD151. Mol Cell Biol 24: 5978–5988.

52. Maumoto A, Hemler ME (1993) Multiple activation states of VLA-4. Mechanistic differences between adhesion to GSL/ fibronectin and to vascular cell adhesion molecule-1. J Biol Chem 268: 228–234.

53. Wright MD, Geary SM, Fitter S, Moseley GW, Law LM, et al. (1995) Characterization of mice lacking the tetraspanin superfamily member CD151. Mol Cell Biol 24: 5978–5988.

54. Masumoto A, Hemler ME (1993) Multiple activation states of VLA-4. Mechanistic differences between adhesion to GSL/ fibronectin and to vascular cell adhesion molecule-1. J Biol Chem 268: 228–234.

55. Yehudt TA, Cannon C, Vandevert C, Goldbach EG, Shaw G, et al. (1995) GPIIb integrin-dependent cell adhesion is regulated by a low affinity receptor pool that is conformationally responsive to ligand. J Biol Chem 270: 2874–28750.

56. Newham P, Craig SE, Clark K, Mould AP, Humphries MJ (1998) Analysis of ligand-induced and ligand-attenuated epitopes on the leukocyte integrin alpha[IIb]beta[3]. J Biol Chem 273: 2874–28750.